Skip to content
Screener
Cingulate logo

Cingulate

CING

Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform.

Market cap
$64.71M+204%

Earnings

Q3 2026 report

November 12, 2026

Next report

Date not yet announced

Competitors

Profile

Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform. The company targets conditions requiring complex daily dosing regimens, such as ADHD and anxiety, by creating once-daily, multi-dose tablets designed to improve patient compliance and treatment outcomes.

Competitive position

Cingulate is a clinical-stage developer seeking to disrupt the ADHD market by addressing the 'booster dose' unmet need through its proprietary erosion barrier layer technology.

GeographiesUnited States, Europe
Customer segmentsPatients, Healthcare Providers, Payers
Business modelDrug Development, IP Licensing
SuppliersActive Pharmaceutical Ingredient (API) suppliers, Contract Development and Manufacturing Organizations (CDMOs), Clinical Research Organizations (CROs)
CustomersWholesale distributors, Pharmacies, Hospitals, Healthcare providers
Listed2021
Employees13.0
CEOShane J. Schaffer
FilingsSEC EDGAR

FAQ

What is Cingulate's market cap?
Cingulate (CING) has a market capitalization of $64.7M and trades on NASDAQ.
Who are Cingulate's competitors?
Cingulate's key competitors include Aytu BioPharma, Inc., Janssen Pharmaceuticals, NRX Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Cingulate partner with?
Cingulate's notable partners include Indegene, Inc., IQVIA Inc., CoreRx, Inc., and others.
What subsidiaries does Cingulate have?
Cingulate's subsidiaries include Cingulate Therapeutics LLC.
Where is Cingulate headquartered?
Cingulate is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2021.